Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Greater China Junior Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Crossy who wrote (318)	10/10/2003 9:45:37 AM
From: Crossy	Read Replies (1) \| Respond to of 1992

re: 1164.HK - Vital Biotech - HK listed - HK$0.64 VITAL BIOTECH Holdings Ltd. 1164.HK - Company ProfileThe Group is mainly engaged in the research, development, manufacture, sale and distribution of biopharmaceutical and conventional pharmaceutical products. Sector Pharmaceutical Chairman Ko Sai Ying Thomas Major Shareholder Tao Lung & Li Chun Yi Directors Ko Sai Ying Thomas(Chairman & Executive Director)Au Yeung Ping Yuen Terrence(Vice Chairman & Executive Director)Liu Jin James(Executive Director)Tao Lung(Executive Director)Lui Tin Nang(Independent Non-Executive Director)Lee Kwong Yiu(Independent Non-Executive Director) Company Secretary Lam Kai Cheung Registered Office Century YardCricket SquareHutchins DriveGeorge TownGrand CaymanCayman IslandsBritish West Indies Head Office 18/F CRE Building303 Hennessy RoadWanchaiHong Kong Share Registrars Computershare Hong Kong Investor Services LimitedShops 1712-171617/F Hopewell Centre183 Queen's Road EastHong Kong Auditors PricewaterhouseCoopers Bankers The Hongkong and Shanghai Banking Corporation LimitedThe Agricultural Bank of ChinaThe Industrial and Commercial Bank of China Legal Advisors Chiu & PartnersShu Jin & Co. Solicitors & AttorneysConyers Dill & PearmanNevett FordArtur dos Santos Robarts Tel. no N/A Fax no N/A E-mail N/A Website www.vitalbiotech.com Vital BioTech 1164 Chairman KO Sai Ying Thomas Issued Capital 1,277M Shares Par Value (HKD) 0.010 Market Capitalisation (HKD) 639M Corporate Profile The Group is principally engaged in the research and development, production and distribution of biopharmaceutical and conventional pharmaceutical products with a focus on downstream value adding biotechnology processing systems. It is a developer of protein stabilization and various drug delivery technologies which may be adapted to a wide range of applications. The Group has commercialized and refined 2 platform technologies: (i) the "Protein Stabilization and Delivery (PSD)" technology, which utilizes micro bio-encapsulation process to achieve room temperature stabilization and mucosal delivery of biological proteins via a non-injection route; and (ii) the "Skin Drug Delivery System (SDDS)" technology, which is used for delivering various chemical drugs to the systemic circulation system through the skin-surface. Utilizing these 2 technologies, the Group has developed 2 products, namely Opin (a medication for chronic erosive cervicitis) and Spray-On Bandage (for wound protection). PSD and SDDS are only manufacturing technologies and have no specific therapeutic claim or efficacy claim, and such claims are claims of the product that uses the technology. Currently, the Group has 22 marketing and liaison offices strategically located in various major cities in the PRC. Its production facilities at Changdu City, the PRC has obtained its PRC GMP approval in Dec 2001 and is expected to commence production during the 1Q2002. (Note: Starting from 4th Aug 2003, the Group's listing status has been shifted from the GEM to the Main Board of the SEHK.) 2002-8-12 08:34:00 a.m. HKT, AFX Vital Biotech plans to switch listing to main board HONG KONG (AFX-ASIA) - Vital Biotech Holdings Ltd (8193.HK) is planning to switch to a main board listing from the GEM board, financial controller KC Lam said. Cited by the Hong Kong Economic Journal, Lam said a main board listing could give the company more flexibility in terms of seeking acquisitions. Lam said the company booked a net profit of over 30 mln hkd in aggregate during 2000 and 2001 financial years. The company will be allowed to switch to the main board if it reports a net profit of 20 mln hkd in the current financial year, he added. The company reported a six months to June net profit of over 18 mln hkd, representing an increase of over 34 pct year-on-year, the paper said. st/jv